Syros Pharmaceuticals Inc. (SYRS)
NASDAQ (NGS) NASDAQ (NGS) Primary 
LSE 
Syros Pharmaceuticals Inc. May Have Infringed On Shareholders' Rights And Those With Losses Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / September 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or "the Company") (NASDAQ:SYRS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Bronstein, Gewirtz and Grossman, LLC Encourages Syros Pharmaceuticals, Inc. (SYRS) Investors to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESSWIRE / September 1, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Syros Pharmaceuticals, Inc. ("Syros" or "the Company") (NASDAQ:SYRS). Investors who purchased Syros securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SYRS.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc. - SYRS
NEW YORK, NY / ACCESSWIRE / August 30, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or the "Company") (NASDAQ:SYRS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
The Schall Law Firm Is Looking Into Whether Syros Pharmaceuticals Is Liable To Stockholders For Breaking Securities Laws And The Firm Wants The Public's Help
LOS ANGELES, CA / ACCESSWIRE / August 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or "the Company") (NASDAQ:SYRS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Individuals With Losses In Syros Pharmaceuticals Inc. Should Join The Schall Law Firm In An Inquiry Into Possible Securities Law Violations
LOS ANGELES, CA / ACCESSWIRE / August 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or "the Company") (NASDAQ:SYRS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Bronstein, Gewirtz and Grossman, LLC Encourages Syros Pharmaceuticals, Inc. (SYRS) Shareholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESSWIRE / August 30, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Syros Pharmaceuticals, Inc. ("Syros" or "the Company") (NASDAQ:SYRS). Investors who purchased Syros securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SYRS.
Stockholders In Syros Pharmaceutical Inc. Are Invited To Join The Schall Law Firm In An Inquiry About Possible Securities Law Infractions
LOS ANGELES, CA / ACCESSWIRE / August 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or "the Company") (NASDAQ:SYRS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Bronstein, Gewirtz and Grossman, LLC Encourages Syros Pharmaceuticals, Inc. (SYRS) Stockholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESSWIRE / August 29, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Syros Pharmaceuticals, Inc. ("Syros" or "the Company") (NASDAQ:SYRS). Investors who purchased Syros securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SYRS.
Syros Pharmaceuticals Being Investigated on Behalf of Syros Pharmaceuticals, Inc. Investors. Contact Levi & Korsinsky For Details.
NEW YORK, NY / ACCESSWIRE / August 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Syros Pharmaceuticals, Inc. ("Syros Pharmaceuticals") (NASDAQ:SYRS) concerning possible violations of federal securities laws. Syros issued a press release on August 12, 2024, "announcing that it will discontinue enrollment in the SELECT-AML-1 Phase 2 clinical trial evaluating the triplet regimen of tamibarotene in combination with venetoclax and azacitidine compared to the doublet regimen of venetoclax and azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia (AML) and RARA gene overexpression.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc. - SYRS
NEW YORK, NY / ACCESSWIRE / August 28, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or the "Company"). [email protected] The investigation concerns whether Syros and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
Syros Pharmaceutical Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Shareholders To Reach Out
LOS ANGELES, CA / ACCESSWIRE / August 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or "the Company") (NASDAQ:SYRS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK CITY, NY / ACCESSWIRE / August 28, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Syros Pharmaceuticals, Inc. ("Syros" or "the Company") (NASDAQ:SYRS). Investors who purchased Syros securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SYRS.
